Pfizer submits data for COVID-19 vaccine in young kids 

New York: Pfizer and BioNTech said that they have submitted its data to European Medicines Agency (EMA) which support use of their COVID-19 vaccine in young kids aged between five and less than 12 years. 

Pfizer vaccine has been approved for use in children over 12 years old in United States (US) and The European Union (EU)—excluding children less than 12.

In October, the companies asked U.S. regulators to also allow emergency use authorization of the vaccine in young children, U.S. Food and Drug Administration’s advisory panel is likely to meet next month to review the data. 

As per reports, children are less vulnerable to severe novel coronavirus, but still they can spread the virus to others, including susceptible populations more at danger of severe illness. 

On September 20, the companies claimed that the Pfizer and BioNTech vaccine has been shown strong immune response in five to eleven year olds in a clinical trial of 2,268-participant.